Inogen (NASDAQ:INGN) Cut to Hold at StockNews.com

StockNews.com cut shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research note published on Thursday morning.

Separately, Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Trading Up 1.8 %

NASDAQ INGN opened at $9.38 on Thursday. Inogen has a 12 month low of $4.93 and a 12 month high of $13.33. The stock has a market cap of $223.43 million, a PE ratio of -4.17 and a beta of 1.04. The stock’s 50 day moving average is $9.62 and its 200 day moving average is $9.60.

Hedge Funds Weigh In On Inogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Inogen by 5.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after acquiring an additional 1,188 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Inogen in the second quarter worth $30,000. BNP Paribas Financial Markets increased its position in Inogen by 13.9% in the third quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after purchasing an additional 5,131 shares during the last quarter. Geode Capital Management LLC raised its stake in Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after purchasing an additional 5,921 shares in the last quarter. Finally, Quarry LP bought a new position in Inogen during the third quarter valued at $59,000. 89.94% of the stock is owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.